The impact of gonadotropin-releasing hormone (GnRH) agonist long compared with GnRH antagonist protocols, under in vitro fertilization conditions on endometrial receptivity, is still debated. Therefore, we compared the effect of both GnRH antagonist and agonist long protocols on the endometrial receptivity by analyzing, to our knowledge for the first time, the global gene expression profile shift during the prereceptive and receptive stages of stimulated cycles under the two GnRH analogue protocols compared with natural cycles in the same patients. For the same normal-responder patients, endometrial biopsies were collected on the day of oocyte retrieval and on the day of embryo transfer after human chorionic gonadotropin administration of a stimulated cycle with either GnRH agonist long or GnRH antagonist protocols and compared with the prereceptive and receptive stages of a natural cycle. Samples were analyzed using DNA microarrays. Gene expression profiles and biological pathways involved during the prereceptive stage to the receptive endometrial transition of stimulated and natural cycles were analyzed and compared for each patient. Both protocols affect endometrial receptivity in comparison with their natural cycle in the same patients. Major differences in endometrial chemokines and growth factors under stimulated cycles in comparison with natural cycles were observed. Such an effect has been associated with gene expression alterations of endometrial receptivity. However, the endometrial receptivity under the GnRH antagonist protocol was more similar to the natural cycle receptivity than that under the GnRH agonist protocol.
INTRODUCTION
Studies comparing gonadotropin-releasing hormone (GnRH) agonist long with GnRH antagonist protocols remain controversial, but data regarding the impact of these protocols on endometrial receptivity also conflict, regardless of approaches to assess endometrial receptivity itself [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . New approaches to the evaluation of endometrial receptivity have been suggested by newly identified molecular biomarkers [12] [13] [14] . Some studies have provided evidence that both GnRH agonist long and antagonist protocols only lightly affect endometrial receptivity in comparison with natural cycles [2, 15] . By contrast, other studies have suggested that the GnRH antagonist protocol has a strong impact on the expression of genes involved in the human endometrial receptivity [3, 16] . Finally, still other studies have provided evidence that GnRH agonist long protocols produce a delay of endometrial receptivity [3, 5, 17] .
The divergence between the results of published studies analyzing the effects of GnRH analogues on endometrial receptivity could be explained by 1) differences in the day of the endometrial biopsies, 2) differences in patient profiles, 3) differences in the protocols used for controlled ovarian hyperstimulation (COS) protocols, 4) inappropriate comparisons between samples, and 5) limited numbers of endometrial samples studied (Table 1 ). In addition, the study design of these microarray data compared endometrial biopsies between natural and stimulated cycles (after luteinizing hormone [LH] peak on Day 2 or Day 5 (LHþ2/5] compared with human chorionic gonadotropin [hCG] 2 days after administraton [hCGþ2] or LHþ7/9 compared with hCGþ7/9) for the same patients without using paired samples [2, 5, [15] [16] [17] [18] , but doing so is a crucial condition to limit the impact of interpatient variability, as we have shown previously [19] .
The aim of the present study was to evaluate the effect of GnRH antagonist versus long protocols on endometrial receptivity by comparing, to our knowledge for the first time, the shift in global gene expression profiles in human endometrial biopsies from normal-responder patients during the early secretory and the midsecretory phases of stimulated cycle with the natural cycle in the same patients (hCGþ2 versus hCGþ5 compared with LHþ2 versus LHþ7).
MATERIALS AND METHODS

Patient Characteristics and Endometrial Biopsies
The study population included 30 young, normal-responder patients referred for Intra Cytoplasmic Sperm Injection (ICSI) for male infertility factor between January 2006 and June 2008 and recruited after written informed consent. These patients were part of our previous study comparing the stimulated cycle effects on endometrial receptivity compared to natural cycles without taking into account COS protocols [19] . This project has received institutional review board approval. All patients had normal serum folliclestimulating hormone, luteinizing hormone (LH), and estradiol on Day 5 and were normal responders during a previous first ICSI attempt under GnRH agonist long protocols (n ¼ 16) (Supplemental Table S1 , all Supplemental Data are available online at www.biolreprod.org). However, some whose ICSI failed were, in a second attempt, stimulated under GnRH antagonist protocols (n ¼ 14). A delay of more than 3 mo without treatments elapsed between the two cycles. During the same natural cycle for each patient and before any COS treatment, two endometrial biopsies were done on Day 2 (LHþ2) and Day 7 (LHþ7) after the LH peak. Because all the patients reported regular cycles, the LH surge was estimated according to the first day of menstruation. Histological analysis was not performed to verify that the LH timing was accurate. Therefore, the possibility for a 1-day delay from the first day of the menstruation cannot be excluded. During COS protocols, as previously described [19] , two endometrial biopsies were done, first on the day of egg collection (hCGþ2) and another on the day of embryo transfer (hCGþ5) after hCG administration. Of the 16 patients treated with GnRH agonist long protocols, nine were not evaluated, because only one endometrial biopsy was performed on hCGþ2. Each biopsy sample was frozen at À808C in RLT RNA extraction buffer (RNeasy Mini kit; Qiagen).
Complementary RNA Preparation and Microarray Hybridization
Total RNA (100 ng) was used to prepare twice-amplified, labeled cRNA for hybridization to HG-U133 plus 2.0 arrays (Affymetrix) as described previously [13, 19] . Each endometrial sample (n ¼ 84) was put individually on a microarray chip.
Data Processing
Scanned GeneChip images were processed using Affymetrix GCOS 1.4 software to obtain an intensity value signal and a detection call (present, marginal, or absent) for each probe set using the default analysis settings and global scaling as first normalization method. Probe intensities were derived using the MAS5.0 algorithm. This algorithm also determines whether a gene is expressed with a defined confidence level or not (detection call). This call can either be ''present'' (when the perfect match probes are significantly more hybridized than the mismatch probes; false discovery rate [FDR] , 0.04), ''marginal'' (0.04 FDR 0.06), or ''absent'' (FDR . 0.06). The microarray data were obtained in our laboratory in agreement with the Minimal Information About Microarray Experiment (MIAME; http://www.mged.org/ Workgroups/MIAME/miame.html) recommendations.
Microarray Data Analysis
The Significant Analysis of Microarrays (SAM; Stanford University) [20] was used to identify genes for which the expression varied significantly between the hCGþ2 and hCGþ5 samples (paired-sample analysis) from patients treated with GnRH agonist long or antagonist protocols and between their respective samples under natural cycles (LHþ2 vs. LHþ7, paired-sample analysis) as control for each group of protocol. SAM provides mean or median fold-change (FC) values and an FDR confidence percentage based on data permutation. To perform the comparison of gene expression profiles between endometrial sample groups, a probe set selection using the absent/present detection call (present in at least four and seven samples in the GnRH agonist long and antagonist sample groups, respectively) and a coefficient of variation (!40%) between samples was first performed before the SAM. Selected gene lists (FC . 2 and FDR , 0.05) were submitted to Ingenuity (http://www. ingenuity.com) and FatiGOþ (http://babelomics2.bioinfo.cipf.es) software to identify the biological mechanisms altered by these gene expression variations [21] .
We also performed an unsupervised hierarchical clustering of samples with our predictor list of endometrial receptivity as previously described [13] . Hierarchical clustering analysis based on the expression levels of varying probes were performed with the CLUSTER and TREEVIEW software packages [22] .
Quantitative RT-PCR Analyses
The RNA (0.35 lg) from endometrial samples (n ¼ 20) was used to generate first-strand cDNA. These cDNAs (2 ll of a 1:3 dilution) were used for quantitative PCR reaction according to the manufacturer's recommendation (Applied Biosytems). The 10-ll reaction mixture consisted of cDNA (2 ll), 2.5 lM primer, and 5 ll of LightCycler 480 SYBR Green I Master 2X (Roche). The amplification was measured during 40 cycles with an annealing temperature at 658C. Quantitative RT-PCR (qRT-PCR) was performed using the LightCycler 480 detection system (Roche) and normalized to PGK1 (phosphoglycerate kinase 1) for each sample using the following formula:
where DCt ¼ Ct control -Ct unknown and E corresponds to the effectiveness of the PCR reaction. This effectiveness is obtained by a standard curve corresponding to the primers used. For each hCGþ5 sample (n ¼ 5 under GnRH agonist long and n ¼ 5 under GnRH antagonist protocols), the corresponding natural sample (LHþ7, n ¼ 10) was used as a control. Each sample was analyzed in duplicate, and multiple water blanks were included with the analysis.
Statistical Analyses
Statistical analyses for qRT-PCR values were performed with SPSS 18.0 software (SPSS, Inc.). A repartition difference between sample groups was considered to be significant when the Kruskal-Wallis nonparametric test gave P , 0.05.
RESULTS
Gene Expression Profiles of Endometrial Receptivity Resulting from GnRH Antagonist Versus Agonist Long Protocols
The SAM analyses were performed between the hCGþ2 and hCGþ5 sample groups for each protocol (hCGþ2 vs. hCGþ5; paired-sample analysis) and between the LHþ2 and LHþ7 control sample groups (LHþ2 vs. LHþ7; paired-sample analysis). The number of genes significantly up-regulated during the receptive stage was similar between the GnRH (7) vs LHþ7 (7) hCGþ2 Ag (7) vs hCGþ5 Ag (7) Yes Strong LHþ2 (14) vs LHþ7 (14) hCGþ2 Atg (14) vs hCGþ5 Atg (14) Yes Strong a n ¼ number of samples. 680 agonist long (731 genes) and antagonist (634 genes) protocols. However, there were twice as many down-regulated genes under GnRH agonist long as under antagonist protocols (451 vs. 210 genes, respectively) (Fig. 1A) . The gene lists identified with SAM analyses between the prereceptive and receptive samples from the stimulated cycle under GnRH agonist long or antagonist protocols were then intersected with their respective prereceptive and receptive samples from the natural cycle used as controls to determine their overlap. The number of down-regulated genes in common between stimulated and natural cycles was similar under GnRH agonist long and antagonist protocols (10% in common with their natural cycle under the GnRH agonist protocol vs. 7% under the GnRH antagonist protocol). Of the genes upregulated during the receptive stage of the natural cycle, 5% matched those up-regulated under GnRH agonist long protocol, whereas 36% were common to the profile resulting from the GnRH antagonist protocol (Fig. 1B) .
Differential Gene Expression Profiles Between GnRH Antagonist and Agonist Long Protocols
To identify genes specifically modulated during the prereceptive to the receptive endometrial transition either under GnRH agonist long or antagonist protocols, we crosslisted the gene lists resulting from each protocol in comparison with their natural cycle. Many genes were commonly regulated under each protocol as compared to the natural cycle (114 upregulated and 77 down-regulated), but each category displayed a specific gene expression profile. Among down-regulated genes specific to the GnRH agonist signature during the endometrial transition, numerous genes were articulated around cell-cycle function and more especially in checkpoint regulation (Fig. 1C) . Among genes specific to this function, the most representative genes were CCNB1 (x-2.2, FDR ¼ 0.005),
, FDR , 0.0001), RAD51 (x-2.6, FDR ¼ 0.007), and SUV39H1 (x-2, FDR , 0.0001). In contrast, only two down-regulated genes resulting specifically from the GnRH antagonist protocol were associated with cell-cycle function: HDAC9 (x-5.7, FDR , 0.0001) and CDC25C (x-3.6, FDR , 0.0001).
We then performed a FatiGOþ analysis on genes upregulated during the prereceptive to the receptive endometrial transition and exclusive to either protocol. The majority of the up-regulated genes localized as intracellular under the GnRH agonist long protocol and were localized to the extracellular space under the GnRH antagonist protocol (adjusted P , 0.05). Biological processes associated with this list of genes included ''response to external stimulus'' and ''defense response'' (adjusted P , 0.05). By contrast, no significant biological processes were associated with the genes up-regulated during the GnRH agonist long protocols. Therefore, for the upregulated genes specific to each protocol, we focused on the gene families with an extracellular localization that regulate the endometrial microenvironment, such as the chemokines and growth factors.
Major Differences of Chemokines and Growth Factors Between GnRH Agonist Long and Antagonist Protocols
Chemokines such as CCL4, CCL8, CCL14, CCL18, CCL21, and CXCL12 were the most important members of the chemokine family up-regulated during the prereceptive to the receptive endometrial transition and exclusive to the natural cycle, whereas CXCL1, CXCL16, and CCL2 were those resulting only from the GnRH antagonist protocols (vs. CXCL5, CXCL6, and CXCL8 from the GnRH agonist long protocols). Three chemokines were common to the natural and the stimulated cycles under antagonist conditions: CXCL13, CXCL14, and CCL8. Conversely, only one gene, CXCL13, was found in common for the natural cycle and the GnRH agonist long protocol ( Fig. 2A) . Both FC and FDR were shown in the Supplemental Table S2A . Some of these genes were validated by qRT-PCR (Fig. 3) .
Regarding growth factors, FGF7, FGF18, HGF, PDGFA, PDGFRA, TGFA, VEGFA, VEGFB, IGFBP1, IGFBP3, IGFBP7, and IGF2BP2 were the up-regulated genes specific to the natural cycle. IGFBP5 was the sole up-regulated gene specifically expressed under the GnRH antagonist protocol, whereas EGF, GDF15, IGF1R, MET, and IGF2BP3 were upregulated only under the GnRH agonist long protocol. Two other genes, HBEGF and MEGF10, were found in the stimulated cycles either under the GnRH antagonist or agonist long protocols, but not in the natural cycle. In addition, HGF, PROK1, and TGFB2 were the three genes found exclusively in common between the natural cycle and the GnRH antagonist protocol. TYMP and FGFR2 were the only two genes in common between stimulated and natural cycles (Figs. 2B and 3) (FC and FDR shown in the Supplemental Table S2B ).
Top-ranked functional networks around these chemokines and growth factors were also identified for each class of GnRH analogues (Supplemental Fig. S1 ).
Biomarkers of Endometrial Receptivity Under Stimulated Cycles
Using our previously described predictor list of the endometrial receptivity [13] for unsupervised clustering of the natural and stimulated cycle endometrium profiles from the same patients during the endometrial shift revealed that both GnRH agonist long and antagonist samples were misclassified (Fig. 4) . However, the signature of endometrial receptivity was more altered under GnRH agonist long than under GnRH antagonist protocols. Impairment of gene expression of endometrial receptivity was also confirmed by the SAM analyses between the prereceptive and the receptive samples showing that only four and three of our five biomarkers were significantly up-regulated under GnRH agonist long and antagonist protocols, respectively. C2CD4B (NLF2) was increased by a factor of 22.5 in the natural cycle versus 11.5 and 5.4 under GnRH agonist long and antagonist protocols, respectively; a factor of 10.2 versus 9.6 under GnRH antagonist cycles for PROK1; a factor of 37 versus 12.9 under GnRH antagonist cycles for MFAP5; a factor of 12.6 versus 3.8 under GnRH agonist long protocols for ANGPTL1; and a factor of 20.4 versus 8.5 and 12.4 under GnRH agonist long and antagonist protocols, respectively, for LAMB3 (Supplemental Table S2C ). However, we found similar variations with a lesser amplitude under stimulated cycles in comparison with natural cycles, suggesting incomplete receptivity during COS protocols. Data obtained from the microarray analyses were previously validated by qRT-PCR [13, 19] .
DISCUSSION
The complex processes of embryo implantation require a multitude of molecules acting locally on the endometrium. In the current study, we report different expression patterns of endometrial chemokines and growth factors between GnRH agonist long and antagonist protocols in comparison with natural cycles, affecting the local microenvironment of endometrial receptivity. Such differences were more important under GnRH agonist long than under GnRH antagonist protocols. Our results support previous findings [2] suggesting that GnRH antagonist protocols mimic the natural endometrial receptivity more closely than GnRH agonist long protocols.
Indeed, in the present study, the gene expression profile comparison during the prereceptive to the receptive endometrial transition revealed that the number of genes in common between stimulated and natural cycles was more important under GnRH antagonist than agonist long protocols (43% vs. 15%). Under the GnRH antagonist protocol, 38% of chemokines and 25% of growth factors identified were also observed FIG. 2. Major differences of chemokines and growth factors involved during endometrial receptivity between natural, GnRH antagonist, and GnRH agonist long protocols. Chemokines (A) and growth factors (B) up-regulated during the endometrial receptivity are shown under natural, GnRH agonist long, and GnRH antagonist protocols. Red indicates not present in natural cycles.
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in natural cycles versus 12.5% and 12.5%, respectively, under the GnRH agonist long protocol. Our predictor list of genes related to endometrial receptivity during natural cycles [13] supported such findings.
We reported that among the genes specifically up-regulated under either of the stimulating protocols as compared with their natural cycles, few were in common, suggesting that protocols affect the endometrial receptivity differently. Accordingly, CXCL1, CXCL16, CCL2, and IGFBP5 were exclusively upregulated during the endometrial transition treated with GnRH antagonists, whereas CXCL5, CXCL6, CXCL8, EGF, GDF15, IGF1R, IGF2BP3, and MET were those exclusively upregulated under GnRH agonist long protocols. The majority of these findings are reported for the first time, except for the expression of IGFBP5, which was previously reported by Liu et al. [18] to be up-regulated under GnRH agonist protocols compared to natural cycles. In addition, the MET gene was recently reported by Horcajadas et al. [5] to be up-regulated during the implantation window and delayed in GnRH agonist long protocols on hCGþ7 as compared to natural cycles of fertile patients included for the egg donation program. Such disparities between studies could arise from differences in experimental design as well as in microarray data analyses [19] . For this reason, we adopted a new study design strategy for microarray analyses in which the gene expression profile shift from the prereceptive to the receptive stages was compared between stimulated and natural cycles in the same patients.
On the other hand, among these specific gene profile signatures, we also reported a decrease in the expression of genes involved in cell-cycle function during the endometrial transition. Although we previously reported that treatment with GnRH analogues during COS has a negative impact on cellcycle function [19] , the present study reveals that this phenotype is exclusively associated to the GnRH agonist long protocols. This finding was consistent with several reports showing that GnRH agonist protocols exert an inhibitory effect on the human endometrial cell cycle both in vivo and in vitro [23, 24] .
Many in vitro fertilization (IVF) teams currently use GnRH antagonists as a second-choice treatment in normal-responder patients who have failed a previous IVF cycle under GnRH long protocols, but in older patients or in those with polycystic ovary syndrome, the pregnancy rate and live birth rates (per embryo transfer) from patients with equal demographic and clinical characteristics are equivalent between the two GnRH analogues treatments [25, 26] . Consequently, and according to our findings, the COS protocols assume a crucial importance. However, whereas GnRH antagonists cause immediate and rapid gonadotropin suppression by competitive occupancy of the GnRH receptor, GnRH agonists exert their suppression action via pituitary desensitization resulting in a residual gonadotropin activity in some patients.
Little is known regarding the potential effects of LH during the follicular cycle of the menstrual cycle on the endometrial functional activation. On the other hand, preovulatory endometrium is exposed to hCG in most currently used COS protocols, but it is not the case under physiologic conditions. Basically, hCG is used instead of LH to perform final follicle growth and oocyte maturation as well as ovulation control moment. Both hCG and LH bind to a common specific receptor (LH/hCG receptor [hCGR]) belonging to the G protein-coupled receptors family [27] . Recent data suggested that LH or hCG may act directly on the uterus [28, 29] . Tesarik et al. [30] reported that endometrial maturation was disturbed in women treated with GnRH agonists, resulting in low endogenous LH concentrations, but can be rescued by midcycle stimulation of LH/hCGR with exogenous hCG, suggesting that LH/hCGR is needed to support endometrial uterine receptivity. Recently, Kolibianakis et al. [31] reported that the prolongation of the follicular phase by delaying hCG administration results in a higher endometrial advancement incidence, based on histological assessments by Noyes' criteria, on the day of oocyte retrieval in GnRH antagonist cycles [32] . The mechanism by which LH/hCG can directly affect uterine receptivity is still unclear. Certain molecules, such as cytokines (LIF, CSF1, and IL1) and integrins, known to be involved in the endometrial receptivity, may be modulated by LH or hCG [33, 34] . Using an intrauterine microdialysis device to administer low doses of hCG (500 IU/ ml) into the uterine cavity of women during the luteal phase, Licht et al. [29] reported that the intrauterine concentration of IGFBP1 was significantly inhibited during the late luteal phase by hCG administration, but not during the implantation window. However, under COS protocols, hCG administration (5000 or 10 000 IU) was performed 36 h before oocyte retrieval, and to our knowledge, no study to date has evaluated its impact on the gene expression profile during endometrial receptivity.
In addition, the presence of endometrial LH/hCGR is still debated. Several authors have reported the expression of LH/ hCGR in both epithelial and stromal cells of the human endometrium by real-time PCR, nested RT-PCR, and Northern and Western blot analysis [35] [36] [37] [38] [39] , whereas others were unable to amplify the full-length LH/hCGR mRNA [40] . These disparities seem to be associated with the low level of LH/ hCGR mRNA, making its detection difficult by RT-PCR technology. In addition, a truncated and nonfunctional form of the receptor could be amplified and may be a mechanism regulating LH/hCGR down-regulation [39, 40] . We also validated the low LH/hCGR mRNA expression using qRT-PCR in the prereceptive and receptive endometrial samples under both natural and stimulated cycles, because it was found to be undetectable on microarray chips technologies (data not shown). Although the profile of endometrial LH/hCGR expression correlates with the theoretical timing of the implantation window, its predictive value as a biomarker of endometrial receptivity under IVF conditions is under investigation [41] .
Other studies have shown that impairment of endometrial receptivity was caused by high serum estradiol and/or progesterone levels under COS protocols [18, 42] . Although estradiol and progesterone have long been believed to be essential for developing an appropriate endometrial environment for blastocyst implantation and are currently used to maintain the luteal phase during IVF, hormones and growth factors secreted by endometrial cell types are able to modulate their effects. In the LH/hCGR knockout model animals, the normalization of serum estradiol and progesterone levels has been shown to be sufficient to restore a normal endometrial receptivity phenotype, including the ability of the uterus to implant donor blastocysts [43] . These findings underline the 684 complexity of signaling pathways controlling endometrial receptivity under stimulated cycles.
In conclusion, the present study provides new information relating to the COS protocol effects on endometrial receptivity under IVF cycle. The transcriptomic pattern of endometrial cells in stimulated cycles reveals differential endometrial receptivity both under GnRH agonist long and antagonist protocols in comparison with natural cycles. However, the results obtained in the present study will need confirmation in additional larger studies.
